Junius Daniel M has submitted a new Form 144/A, indicating plans to sell shares of IDEXX Laboratories Inc. This filing, dated November 5, 2026, is noteworthy as it highlights a significant transaction involving the company's common stock.

IDEXX Laboratories, based in Westbrook, Maine, is a prominent player in the diagnostics industry, particularly in the in vitro and in vivo diagnostic substances sector. The company is known for its innovative solutions in veterinary diagnostics and water testing.

The filing reveals that Junius Daniel M, who serves as a director at IDEXX, sold a total of 1,200 shares through two transactions on November 4, 2026. The first transaction involved the sale of 700 shares with an aggregate market value of $494,043, facilitated by Sanford C. Bernstein & Co., LLC. The second transaction involved the sale of 500 shares valued at $345,835, executed through Fidelity Brokerage Services LLC. The total market value for these transactions amounts to approximately $839,878.

According to the filing, the shares sold were acquired through an open market purchase back on August 3, 2015. This indicates that Junius has held onto these shares for a considerable period before deciding to sell.

This transaction may have implications for other stakeholders, including investors and analysts monitoring IDEXX Laboratories and the broader diagnostics industry. The sale of shares by a director can sometimes signal a shift in confidence or strategy, prompting market participants to reassess their positions.

The filing does not specify what actions might follow this sale or if there are plans for additional transactions. As such, the market will be watching closely for any further developments from Junius Daniel M and IDEXX Laboratories.